Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Net Cash Flow (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Net Cash Flow for 9 consecutive years, with -$7.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Net Cash Flow fell 396.39% to -$7.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $11.4 million, a 193.91% increase, with the full-year FY2024 number at $11.4 million, up 177.82% from a year prior.
  • Net Cash Flow was -$7.1 million for Q4 2024 at SELLAS Life Sciences, down from $11.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $27.1 million in Q4 2020 to a low of -$9.8 million in Q3 2023.
  • A 5-year average of $680550.0 and a median of -$3.5 million in 2020 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: surged 1559.29% in 2020, then plummeted 1268.93% in 2021.
  • SELLAS Life Sciences' Net Cash Flow stood at $27.1 million in 2020, then plummeted by 118.18% to -$4.9 million in 2021, then grew by 14.27% to -$4.2 million in 2022, then skyrocketed by 65.92% to -$1.4 million in 2023, then crashed by 396.39% to -$7.1 million in 2024.
  • Per Business Quant, the three most recent readings for SLS's Net Cash Flow are -$7.1 million (Q4 2024), $11.9 million (Q3 2024), and -$9.3 million (Q2 2024).